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Although it has been previously demonstrated that adminis-
tration of anti-vascular endothelial growth factor (VEGF)
receptor-2 antibodies to hypophysectomized (Hx) mice during
gonadotropin-stimulated folliculogenesis and luteogenesis
inhibits angiogenesis in the developing follicle and corpus
luteum (CL), it is unclear which of the many components of
VEGF inhibition are important for the inhibitory effects on
ovarian angiogenesis. To examine whether ovarian angiogen-
esis can be more specifically targeted, we administered an
antibody to VE-cadherin (VE-C), an interendothelial adhesion
molecule, to Hx mice during gonadotropin stimulation. In tu-
mor models and in vivo and in vitro assays, the anti-VE-C
antibody E4G10 has been shown to specifically inhibit angio-
genesis, but VE-C has yet to be inhibited in the context of
ovarian angiogenesis. In addition to studying the effect on
neovascularization in the follicular and luteal phases, we also
examined the effect of E4G10 on established vessels of the CL
of pregnancy. The results demonstrate that E4G10 specifically
blocks neovascularization in the follicular and luteal phases,
causing an inhibition of preovulatory follicle and CL devel-
opment, a decrease in the vascular area, and an inhibition of
function demonstrated by reduced hormone levels. How-
ever, when administered during pregnancy, unlike anti-
VEGF receptor-2 antibody, E4G10 is unable to cause dis-
ruption of the established vessels of the mature CL. These
data demonstrate that E4G10 causes a specific inhibition of
neovascularization in the ovary without destabilizing pre-
existing vasculature. (Endocrinology 146: 1053–1059, 2005)
DEVELOPMENT OF THE preovulatory follicle and thecorpus luteum (CL) are processes that are critically
dependent on angiogenesis (1). New blood vessels provide
substrate for steroidogenesis, allow for delivery of endocrine
and paracrine factors to and from the follicle and CL, and
supply the preovulatory oocyte with oxygen and other met-
abolic needs. Manipulation of ovarian angiogenesis may be
of therapeutic value by allowing potential augmentation or
inhibition of follicular or luteal function, depending on the
desired clinical outcome.
The relationship between angiogenesis and ovarian func-
tion has been well established, most notably by inhibiting the
activity of vascular endothelial growth factor (VEGF) and its
receptors. VEGF has multiple roles: an endothelial cell mi-
togen, a vascular survival factor, and an inducer of micro-
vascular permeability (2). Studies of rodents and primates
have shown that immunoneutralization of VEGF by soluble
receptors or receptor-blocking antibodies during the ovarian
cycle causes inhibition of angiogenesis and impaired devel-
opment of preovulatory follicles and the CL (3–7). These
studies implicate VEGF as an important mediator of ovarian
angiogenesis but do not address which specific functions are
necessary for angiogenesis.
To investigate angiogenic modulation of ovarian vascu-
lature by inhibition of endothelial cell assembly into vascular
structures, we chose to target vascular-endothelial cell cad-
herin (VE-C), an angiogenesis-related adhesion molecule.
VE-C, also known as CD144/cadherin-5, is a 125-kDa single-
pass transmembrane glycoprotein that associates as cis-
dimers via the extracellular domains (ECD) on the cell to
promote intercellular homophilic adherens junctions (8, 9).
The cytoplasmic domain is anchored to the actin cytoskele-
ton via proteins of the armadillo family, specifically -cate-
nin, plakoglobin, and p120 (10, 11). The association with actin
may be important in modulating paracellular permeability,
stabilization of the junctional complex, and intracellular sig-
naling (8, 10). A null mutation in the VE-C gene results in
embryonic lethality by embryonic d (E)9.5–10 with the in-
ability of normally differentiated endothelial cells to form
vascular structures (12). The involvement of the ectodomain
and the distribution of the VE-C complex on the cell surface
are thought to be dynamic and variable with the functional
state of the cell.
An antibody to the NH2-terminal portion of the ECD of
VE-C (E4G10; ImClone Systems) was developed and char-
acterized that specifically inhibits angiogenesis by prevent-
ing new adherens junction formation between endothelial
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cells without disrupting preexisting junctions (13–15). The
efficacy of this agent has been studied using in vitro and in
vivo angiogenesis assays and in tumor models but has yet to
be investigated under physiological conditions.
To examine the role of VE-C in ovarian angiogenesis, we
administered E4G10 during stimulated ovarian cycles in hy-
pophysectomized (Hx) mice. Follicular maturation and ovu-
lation are normally absent in these animals but can be reliably
induced with exogenous gonadotropins (16, 17). Because
they lack endogenous ovarian-hypothalamic-pituitary feed-
back, preovulatory follicle and CL development is not con-
founded by internal hormonal interactions or the effect of
antiangiogenic substances on hypothalamic-pituitary re-
sponse. We demonstrate that the presence of an anti-VE-C
antibody blocks follicular and luteal angiogenesis, conse-
quently inhibiting the ability of gonadotropins to normally
stimulate the development of the preovulatory follicle and
CL. To examine the ability of anti-VE-C to disrupt mature
vessels, we administered E4G10 to pregnant mice with an
established CL. With this model, we demonstrate that VE-C
inhibition does not cause disruption of mature vasculature;
this is in contrast to a VEGF-receptor (VEGFR) antagonist
that destabilizes the vasculature of the CL even after it is
established in pregnancy. These data suggest a dynamic,
specific role of VE-C in ovarian angiogenesis, making it an
attractive target for selective inhibition of growing vessels.
Materials and Methods
Angiogenesis and development of the preovulatory follicle
and CL
Anti-VE-C antibody. E4G10 monoclonal antibody against an epitope cor-
responding to a region of the NH2-terminal domain of murine VE-C was
generated as previously described (13).
Ovulation induction and antibody treatment. Female CD-1 mice Hx before
24 d of life (Charles River Laboratories Inc., Wilmington, MA) were used.
In Hx mice, follicular development is arrested at the advanced preantral
or early antral stage because of lack of endogenous gonadotropins but
can reliably develop mature follicles that can be triggered to ovulate if
exogenous gonadotropins are administered (18). After arrival, animals
are allowed to equilibrate for 1 wk. The lack of significant weight gain
(1.5 g) and vaginal smears consistent with a hypoestrogenic state
indicate successful hypophysectomy. Only mice that meet both criteria
were included in the experiments. Antibody dosing (250 mg/kg) was
empiric, based on previous experiments of dose response (not pub-
lished). Mice were treated humanely in accord with the policies set forth
by the Institutional Animal Care and Use Committee of Columbia
University.
For the follicular phase (n  12 per group), Hx mice were treated with
1 ip injection of 20 IU pregnant mare serum gonadotropin (PMSG)
(Sigma Chemical Co., St. Louis, MO) 1 wk after arrival to stimulate
gonadotropin-dependent follicular development. Treatment animals
were given 1 ml ip injections of E4G10 (4 mg/ml) (ImClone) 12 h before
and 48 h after the PMSG injection. Control animals received ip saline
injections (1.0 ml) at 12 and 48 h after PMSG. Animals were killed 24 h
after the last injection (72 h after PMSG).
For the luteal phase (n  12 per group), Hx mice were injected ip with
20 IU PMSG as above and 72 h later with 20 IU human chorionic
gonadotropin (hCG) (Sigma) to induce ovulation and CL formation.
Treatment animals received a single 1-ml injection of E4G10 (4 mg/ml)
2 h before hCG; control group animals received 1.0 ml of saline instead
of antibody. Animals were killed 24 h after hCG treatment.
Specimen collection. Immediately after killing, blood was obtained via
cardiac puncture for hormonal analysis. Both ovaries and one kidney
were carefully dissected. The kidney and one ovary were snap frozen in
OCT and stored at –80 C in preparation for frozen sectioning. The
contralateral ovary was weighed after drying on fluid-adsorbing paper,
and then preserved in formalin for serial sectioning and hematoxylin
and eosin (H&E) staining.
Histology and immunohistochemistry. Formalin-fixed ovaries were sec-
tioned at 10-m intervals, and each section was stained with H&E.
Evaluation of H&E sections through entire ovaries were used for dif-
ferential follicle and CL counting and qualitative comparison of devel-
opment of follicles and CL. Frozen blocks were sectioned at 10-m
intervals by standard histological protocols. Antibody to platelet endo-
thelial cell adhesion molecule (PECAM)/CD31 (PharMingen, San Diego,
CA) was used to identify blood vessels according to manufacturer’s
protocols. Rabbit antirat IgG was used as secondary antibody (Sigma-
Aldrich, Milwaukee, WI). Peroxidase staining with diaminobenzidine
tetrachloride (DAB) brown chromogen was used to identify the sec-
ondary antibody (DAB substrate kit; Vector Laboratories, Burlingame,
CA). Hematoxylin was used for counterstaining.
To verify expression of VE-C in the control ovaries, follicular and
luteal phase serial sections were stained with two different primary
VE-C antibodies: E4G10 and RDI-MCD144–11D4 (Research Diagnostics,
Flanders, NJ). Secondary antibody and peroxidase staining were per-
formed in the usual fashion.
Image analysis. For follicular and CL counting, formalin samples em-
bedded in paraffin were sectioned at 10-m intervals through their
entirety. Gonadotropin-dependent follicles as defined by Pedersen’s
classification of mouse follicles as stage 6 or greater (19) were counted
in serial sections. CL were identified by morphological properties con-
sistent with luteinized follicles and counted in serial hematoxylin sec-
tions. Two independent investigators corroborated follicular and CL
counts.
For vascular density, the largest-diameter sections of each follicle and
CL were analyzed under a light microscope coupled with a Nikon
Eclipse E800 digital camera. Images were analyzed with ImagePro Plus
version 4.01 software (Media Cybernetics, Silver Spring, MD). Images
were calibrated for magnification, and follicles and CL were measured
for diameter and largest cross-sectional area. To assess vascular area,
PECAM staining was visually identified as DAB brown staining. These
areas were selected for counting. The software identified all other areas
with equivalent image properties as the selected area and included them
for measurement of vascular area.
In the preovulatory follicles, the thecal area of the largest cross-section
was measured, and the endothelial area identified by PECAM-positive
cells within this compartment was identified. The area occupied by
vasculature was measured and expressed in micrometers (2). In the CL,
the vascular density was also calculated as the ratio of the area of
PECAM-positive cells to the largest cross-sectional area of the CL.
To examine the effect of E4G10 on permanent vasculature, 10-m
frozen sections of kidney were stained with PECAM in control and
treatment animals.
Hormonal assays. Blood obtained via cardiopuncture was allowed to clot
for 1 h and then centrifuged at 900  g for 10 min at room temperature.
Serum was aspirated, and estradiol and progesterone were measured
with ligand-labeled, competitive, chemiluminescent immunoassay (Di-
agnostic Products Corp., Los Angeles, CA). The interassay coefficients
of variation were 11.9 and 11.1% for estradiol and progesterone,
respectively.
Statistical analysis. Data are expressed as mean  se. Student’s t test was
used with P values 0.05 considered significant, using GraphPad Prism
version 3.00 for Windows (GraphPad Software, San Diego, CA).
Blood vessel maintenance in the CL of pregnancy
CD1 male and female mice were mated overnight, and vaginal plugs
were checked in the midmorning to confirm coitus. Postcoital females
were weighed and separated into individual cages. On E6.5, all mice
were weighed and divided into three groups (n  5 per group). Group
1 consisted of control animals that received no further treatment. Group
2 mice received 1 ip injection of E4G10, 4 mg. Group 3 animals received
1 ip injection of anti-VEGFR-2/Flk1 antibody (DC101; ImClone), 2.5 mg.
DC101 has a known antiangiogenic effect on the CL of pregnancy; ip
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administration on E3.5 causes disruption of CL vasculature resulting in
prevention of further development of the pregnancy (34). DC101 does
not cross the placenta; thus, the antiangiogenic action affects the CL but
not the placenta or fetus. On E13.5, mice were weighed and killed. Blood
was obtained by cardiac puncture, and serum was assayed for proges-
terone as above. Uteri were dissected and weighed, and two fetuses per
uterus (if present) were dissected, weighed, and preserved in formalin.
Ovaries were dissected, weighed, and snap frozen in OCT. Frozen sec-
tioned ovaries were stained for PECAM by standard immunohisto-
chemical methods, and ImagePro software was used to calculate CL
vascular density, as above.
Results
VE-C is expressed in the ovary
Expression of VE-C in the ovary was verified with immu-
nohistochemistry using two different primary antibodies.
E4G10 displayed only weak affinity for vasculature, even at
high concentrations. However, MCD144-11D4 showed
marked localization to thecal and luteal vasculature (Fig. 1).
This expression of VE-C colocalized with anti-PECAM stain-
ing (not shown), verifying specificity to endothelial cells.
E4G10 inhibits follicular angiogenesis and development
Table 1 summarizes follicular phase results. Follicular de-
velopment in control animals was uniform with distinct lo-
calization of PECAM to the thecal layer, whereas treatment-
group follicular development appeared disorganized with
scant PECAM staining in the thecal layer (Fig. 2). The weight
of treatment group ovaries was significantly lower than the
weight of control group animals. The number of gonado-
tropin-induced preovulatory follicles per ovary in treatment
animals was significantly less than controls. In the treatment
group, the advanced follicles were mostly stage 6, with few
if any stage 7 or 8 follicles per ovary. The maximum cross-
sectional area of the most advanced treatment group follicles
was significantly smaller when compared with preovulatory
control group follicles. The vascular area detected in the
theca layer of the most advanced treatment group follicles
was significantly less than that of similar control group fol-
licles. Also, the blood vessel density, calculated by dividing
the vascular area by the total thecal area multiplied by 100,
was significantly less in the treatment group compared with
controls. Estradiol levels in the treatment group were sig-
nificantly lower than the control group. The weight of treat-
ment mice did not significantly differ from controls before or
after treatment. No mouse in either control or treatment
group exhibited signs of toxicity.
E4G10 inhibits luteal angiogenesis and development
Table 2 summarizes luteal phase results. Control animals
appeared to have uniform development of CL with distinct
staining of vasculature within the luteinized granulosa layer,
whereas the treatment animals appeared to have disorga-
nized luteal development with a paucity of PECAM staining
and unovulated preovulatory follicles (Fig. 3). The weight of
treatment group ovaries was significantly lower than the
weight of control group ovaries. The number of CL in treat-
ment group ovaries was significantly less than that in the
control group. The maximum cross-sectional area of treat-
ment group CL was also significantly reduced compared
with controls. The amount of vasculature formed in treat-
ment group CL was significantly reduced relative to the
control group CL. The percentage of vascular area of the
entire CL area was significantly less in treatment animals
compared with controls. Serum progesterone levels were
significantly lower in treatment mice compared with control
mice. The weight of treatment mice did not significantly
differ from controls before or after treatment. No mouse in
either control or treatment group appeared to exhibit signs
of toxicity.
E4G10 does not disrupt the CL of pregnancy
All animals had a similar weight gain between E1 and E6.5.
The control and E4G10 mice continued to have a similar
degree of weight gain between E6.5 and E13.5, consistent
with normal pregnancy. Anti-VEGFR-2 (DC101) treated mice
had a net weight loss between E6.5 and E13.5. Comparison
of the results from the three experimental groups are sum-
marized in Table 3. Uterine and fetal weights were not sta-
tistically significant between the control and the E4G10
groups, and the number of implantation sites between these
FIG. 1. VE-cadherin expression confirmed in ovary as identified by
anti-VE-C antibody, MCD144-11D4. Expression overlaps with ex-
pression of PECAM, localizing to vascular endothelial cells.




5.70  0.54 3.50  0.55
Advanced follicu-
lar area (m2)
1.6  105  1.34  104 1.09  105  1.71  104
Thecal vascular
area (m2)
3440  266.4 987.2  243.8
Vascular density
(%)
12.7  2.5 1.2  0.98
Estradiol (pg/ml) 63.59  5.14 38.51  2.91
Values are mean  SE; P  0.05.
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two groups was statistically similar. Fetuses in the E4G10
group appeared normal compared with controls in size and
morphology. The anti-VEGFR-2 group had a significantly
lower average uterine weight compared with the control and
E4G10 groups, and no discernable fetuses were visible on
E13.5. Immunohistochemical staining to PECAM of ovarian
sections showed similar total vascular area in the control and
E4G10 groups, whereas the DC101 group had significantly
decreased vascular area. Serum progesterone levels were
similar between the control and E4G10 groups but signifi-
cantly lower in the DC101 group
E4G10 does not affect permanent vasculature of the kidney
H&E and immunohistochemistry staining of renal glo-
meruli against PECAM was comparable between controls
and treatment animals in follicular and luteal phases. The
overall number of glomeruli and morphology were similar
between treatment and control groups in both follicular and
luteal phases.
Discussion
VE-C is shown here for the first time to be expressed in
ovarian vasculature and essential for proper ovarian angio-
genesis. Inhibition of VE-C with an immunoneutralizing an-
tibody, E4G10, during gonadotropin-induced ovarian stim-
ulation results in inhibition of follicular and CL angiogenesis.
Preventing junction formation between endothelial cells by
blocking VE-C with E4G10 inhibits neovascularization but
does not disrupt preexisting junctions. Established vascula-
ture of the CL of pregnancy was unaffected by E4G10 ad-
ministration. Thus, we conclude that anti-VE-C specifically
inhibits neovascularization in the ovary but, unlike anti-
VEGFR-2, does not cause vascular disruption.
Inhibition of new blood vessel development has signifi-
cant effects on ovarian function. In the follicular phase, the
thecal vascular area of the treatment group was decreased by
72% compared with controls. There were fewer advanced
follicles in the treatment group, corresponding to the smaller
average antral follicle size in the treatment group compared
with controls. The morphological findings correlated with
functional findings, because estradiol levels in treatment
mice were reduced by 40% compared with controls. The
greater increase in ovarian weight of controls compared with
treatment also corresponds with the lesser degree of hyper-
trophic gonadotropin effect on E4G10-treated ovaries.
Findings in the luteal phase were similar. The vascular
area of the CL was reduced by 90% in the treatment group
compared with controls. The number of CL and the size of
the largest CL were also significantly reduced in the treat-
ment group. The serum progesterone levels in treatment
mice were reduced by approximately 60% compared with
controls. As in the follicular phase, ovarian weight was less
in the treatment animals, reflecting a lesser degree of stimula-
tion-induced hypertrophy. Because the E4G10 was adminis-
FIG. 2. Follicular phase. A, Control; PECAM staining (brown) iden-
tifies discrete localization to thecal layer around well-developed pre-
ovulatory follicles; B, E4G10-treated, showing sparse PECAM stain-
ing surrounding few advanced follicles.




7.283  0.58 4.050  0.64
CL area (m2) 1.74  104  5.06  103 6.38  104  8.5  103
CL vascular
area (m2)
1.31  103  2.47  103 1.50  103  2.99  102
Vascular
density (%)
8.41  1.45 2.1  0.37
Progesterone
(ng/ml)
8.409  1.162 3.244  0.5783
Values are mean  SE; P  0.05.
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tered before hCG, it is theoretically possible that ovulation was
partially inhibited or may have occurred abnormally as a result
of impaired preovulatory angiogenesis. In the follicles that ovu-
lated, luteinization occurred, but the degree of angiogenesis and
hormonal secretion was dramatically reduced. These effects
may have been a result of abnormal ovulation or the inhibition
of angiogenesis in the early CL. By administering E4G10 shortly
before triggering ovulation, we intended to ensure that anti-
body would be in circulation at the time of early CL develop-
ment, but we cannot rule out the possibility that some of the
effects may have been secondary to inhibition of ovulation. The
experiments during pregnancy demonstrate that once estab-
lished, the CL vasculature and function is unaffected by E4G10
treatment.
It is interesting to note that in both the follicular and luteal
phases, the degree of vascular inhibition does not linearly
correlate with the degree of functional inhibition. That is, the
hormonal secretion from the follicles and CL is suppressed
to a lesser degree than the vascular area within these struc-
tures. This suggests that under physiological conditions,
blood vessel development occurs to a greater degree than is
necessary for normal endocrine function, such that normal
hormonal secretion can be supported by less than maximal
vascular proliferation. Furthermore, the degree of inhibition
of follicular angiogenesis and growth to the preovulatory
stage by antagonizing VE-C was of a similar magnitude as
the inhibition caused by VEGFR-2 inhibition with DC-101 (7).
Because DC101 is known to have significant effects on in-
hibiting vascular permeability, whereas E4G10 does not af-
fect permeability (13), changes in permeability are perhaps
less important to ovarian angiogenesis than previously pro-
posed (20). In contrast, inhibition of VEGFR-2 function had
more significant consequences for CL function (5) than did
inhibition of VE-C. Because VEGFR-2 is required for both
proliferative and permeability responses to VEGF, our data
may suggest that both processes are required for full CL
function.
To examine the effects of VE-C inhibition on mature ovar-
ian vasculature, we treated pregnant mice with E4G10. Al-
though neovascularization is highly active in the CL during
the early luteal phase, the pregnant state represents a time
when the CL vessels have already maximally proliferated
such that vascular stabilization and maintenance appear to
be more significant processes than neovascularization in the
pregnant CL (21, 22). When injected into pregnant mice on
E6.5, E4G10 appeared to have no effect on either the CL or
the developing fetuses. CL stained with equal vascular den-
sity in both control and E4G10 groups. In contrast, VEGFR-2
inhibition appears to not only inhibit neovascularization but
also cause destabilization of mature vessels in the pregnancy
CL. Vessels in other organ systems, such as the renal glo-
meruli, do not appear affected by anti-VEGFR-2 treatment.
Thus, it appears that the recently established vasculature of
the CL may be dependent on VEGF for maintenance and
stabilization, whereas quiescent vasculature may be stabi-
FIG. 3. Luteal phase. A, Control; dense PECAM staining (brown)
identifies vessels within several well developed CL; B, E4G10-treated,





8.27  1.30a 8.1  0.63a 0.27  0.13
Implant sites 12.5  2.5a 11  3.0a 0
Fetal weight
(mg)
155  19.7a 167.3  19.59a 0
Progesterone
(ng/ml)
24.23  1.86a 27.44  4.97a 1.95  0.89
Vascular density
(m2)
11935  3054a 10997  4687a 2209  741
Values are mean  SE.
a P  0.05 compared with anti-Flk.
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lized by non-VEGFR-2 mechanisms. Administration of
DC101, an anti-VEGFR-2 antibody, causes a dramatic dis-
ruption of the vessels of the pregnancy CL, resulting in an
interruption of the ongoing pregnancy. E4G10, however,
causes no discernable effect on the pregnancy CL compared
with controls. In part, the difference in effect between anti-
VEGFR-2 and anti-VE-C inhibition may involve permeability
effects; anti-VEGFR-2 has demonstrated significant effects on
permeability during early pregnancy (23, 24), whereas VE-C
inhibition may not affect vascular permeability (13, 15). It
appears that E4G10 specifically targets formation of new
blood vessels by preventing interendothelial adherens junc-
tions, without disrupting those that are preexisting. Thus, we
concur with other investigators that E4G10 binds an epitope
of the VE-C ECD that is involved in angiogenesis but is either
insignificant to junctional maintenance or inaccessible once
the junction is formed, secondary to conformational change
(13, 15). In addition, it appears that the expression of VE-C
and VEGF are related, although the details of their relation-
ship have yet to be fully elucidated (25, 26).
In conclusion, these data support previous studies that
have demonstrated that angiogenesis in the ovary is im-
portant for follicular and luteal function. Angiogenesis is
a process that occurs as a result of multiple events that
include degradation of the extracellular matrix; budding,
proliferation, and migration of endothelial cells; formation
of capillary tubes; remodeling of capillary networks; and
maturation and stabilization of vessels involving the re-
cruitment of stromal cells (27). Because multiple steps are
involved in the process, many targets are available for
modulation of angiogenesis for various potential clinical
purposes (28). The mechanism of angiogenic inhibition
that we propose here is the prevention of adherens junc-
tion formation, such that new vessels cannot form,
whereas the integrity of established vasculature is pre-
served. E4G10 provides a potent mechanism for specific
inhibition of ovarian neovascularization without disrupt-
ing mature vessels. The lack of effect on mature vessels
would presumably reduce undesirable side effects of per-
meability changes possibly associated with other angio-
genic therapies (29). The clinical applications of specific
ovarian neovascular inhibition potentially include contra-
ception (30), prevention of recurrent ovarian cysts (31),
management of polycystic ovary syndrome (32), and ad-
juvant treatment for malignant ovarian disease (33).
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